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Background: Treatment of blast phase chronic myeloid leukemia (BP-CML) remains a challenge, and the median
survival is less than 6 months. Because effective treatments are lacking, we studied tight targeting of blast crisis
CML cells using adenoviral (Ad) vectors expressing a HSV-TK system under dual control of a specific SUZ12 promoter
and an antioxidant response element (ARE).
Methods: A potential SUZ12 promoter fragment was designed with bioinformatics databases and identified with a
luciferase assay. Next, we cloned the ARE element of the NQO1 gene and developed Ad vectors expressing TK kinase
or luciferase under the dual control of a specific SUZ12 promoter and an ARE element. An in vitro transfection assay
with Ad-ARE/SUZ12-Luc was used to determine promoter activity of ARE/SUZ12 regulatory element in blast crisis CML
cells. After incubating human BP-CML-derived cells with Ad-ARE/SUZ12-TK and ganciclovir, Western blot, CCK8,
Immunofluorescent assays and Annexin V assays were conducted to assess the efficacy of an ARE/SUZ12 dual-specific
TK/GCV system for BP-CML cell lines.
Results: Here, luciferase data confirmed significantly higher and specificer promoter activity of the ARE/SUZ12 composite
component in CML blast crisis-derived cell lines (K562, KCL22, and K562/G01) compared to HepG2 cells, and Ad-AS-TK/
GCV system could exhibit enhanced apoptotic effects and decreased cell viability for BP-CML cell lines. Additionally,
Ad-AS-TK/GCV system altered expression of cycle-related and apoptosis-related proteins in BP-CML cell lines.
Conclusions: Thus, ARE/SUZ12 dual targeting TK/GCV system was effective in killing BP-CML cells. Moreover, efficacy
and specificity of CML cell eradication were enhanced by synergistic effects of ARE/SUZ12 dual-specific regulation. We
conclude that suicide gene-targeted therapy might hold promise for BP-CML treatment.
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Chronic myeloid leukemia (CML) is a clonal myelopro-
liferative disorder of hematopoietic stem cells, account-
ing for 20% of newly diagnosed adult leukemia cases.
The natural history of CML is a stereotypical progres-
sion from the chronic phase (CP), through progressive
deterioration to a final fatal blast crisis phase (BP) [1].
The introduction of tyrosine kinase inhibitors (TKIs) has
dramatically altered CP-CML outcomes [2], improving
8-year overall survival (OS) from 20 to 85%; however, BP-
CML remains a challenge, with a 75% mortality within six* Correspondence: fengwlcqmu@sina.com
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unless otherwise stated.months. Until now, BP-CML treatment has lacked a thera-
peutic agent, and allogeneic stem cell transplantation
(alloSCT) has been considered as the only curative option
for BP-CML, even though post-transplantation prognosis
is poor (2-year OS rate of 16%) [3]. To overcome limita-
tions of current therapy methods, gene therapy has been
suggested to be as a potential novel approach for BP-CML.
Suicide gene therapy has been proved non-invasive
and effective for ovarian cancer, central nervous system
tumors, and graft-versus-host disease (GVHD) syndrome
treatment [4–6]. Among suicide gene therapy strategies,
the herpes simplex virus thymidine kinase gene (HSV-
Tk)/ganciclovir (GCV) system is the most commonly
used for tumor treatment research. Basically, a suicide
gene strategy is based on expressed enzymes of trans-
genes, which convert a non-toxic prodrug into a toxicis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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toxic phosphorylated form that subsequently induces
apoptosis by inhibiting DNA synthesis and blocking the
cell cycle. Additionally, a distant bystander effect of the
TK/GCV system, the regression of tumors distant from
those cells expressing TK, occurs in vivo mainly via im-
mune stimulation. Therefore, the TK/GCV suicide gene
system is a powerful strategy for cancer gene therapy.
SUZ12 is a core component of polycomb repressive
complex 2 (PRC2), essential for regulation of embryo-
genesis, tissue development, and stem cell self-renewal.
SUZ12 is both highly and specifically expressed in stem
cells, and rapidly down-regulated during differentiation.
In normal human tissues, SUZ12 expression is restricted
to proliferating cells in reactive lymphoid tissue, germi-
nal cells in the testis and the epithelium of various or-
gans [7]. Recently, studies have shown that substantial
SUZ12 expression can promote cell proliferation, inhibit
cell differentiation, disrupt histone modification dynamics
and, consequently, induce tumorigenesis [8–11]. More-
over, high promoter activity of the SUZ12 gene have been
shown to be involved with upregulated SUZ12 expression
and colon or liver tumor progression [12]. Pizzatti’s group
reported high promoter activity of SUZ12 in BP-CML
mononuclear cells but a lack of SUZ12 expression in
normal counterparts, because the noncanonical WNT
pathway activates the SUZ12 promoter in BP-CML
cells [13,14].
CML is a clonal myeloproliferative disorder resulting
from a balanced translocation between the long arms of
chromosomes 9 and 22, which generates the hybrid
BCR-ABL gene on chromosome 22q. The product of the
BCR-ABL oncogene is a bcr-abl protein which has high
tyrosine kinase activity. As a potent kinase, BCR-ABL
constitutively produces intracellular ROS [15,16], which
activates the nuclear factor E2-related factor 2 (Nrf2)
pathway. High intracellular ROS in BP-CML activate
Nrf2 to recognize the antioxidant response element
(ARE) of antioxidant responsive genes and drive expres-
sion of nuclear ARE-regulated genes. In normal cells
under homeostatic conditions, Nrf2 is generally localized
to the cytoplasm and is constantly degraded via Keap1-
mediated ubiquitination, thus, the ARE element of
downstream genes was silenced.
In this study, different potential SUZ12 promoter se-
quences were cloned based on bioinformatic predictions
and identified by luciferase assay. Then, we constructed
a BP-CML cell-specific regulatory element composed of
a SUZ12 promoter and an ARE element from the NQO1
gene. Finally, we explored the feasibility of combining
the SUZ12 promoter and an ARE regulatory element to
target BP-CML cells with high specificity. Although pro-
spective results of gene therapy have been reported [17],
strategies are needed to overcome current gene therapyissues such as non-specific normal cell death and cyto-
toxicity. Here, we report that ARE/SUZ12-regulated
HSV-TK/GCV therapy is effective and specific for BP-
CML cells in vitro, and this may offer an attractive
therapeutic approach for treating BP-CML in the future.
Methods
Cell culture
Human BP-CML derived K562, KCL22 and imatinib-
resistant K562/G01 cell lines were maintained in RPMI-
1640 medium (Sigma, USA) supplemented with 10% (v/v)
FBS (Sigma), 100 U/ml penicillin, and 100 μg/ml strepto-
mycin. Ad293, Phoenix-Ampo and HepG2 cell lines were
maintained in Dulbecco’s Modified Eagle’s Medium
(Sigma) supplemented with 10% (v/v) FBS, 100 U/ml peni-
cillin, and 100 μg/ml streptomycin. Cell cultures were
maintained at 37°C under 5% CO2.
Bone marrow samples
Bone marrow samples were obtained from CML patients
and healthy donors admitted or registered at the first
Affiliated Hospital of Chongqing Medical University
(Chongqing, China), according to the guidelines of the
local Ethics Committee. Bone marrow mononuclear
cells were isolated from 2-ml aspirates using Ficoll gra-
dient (Tianjin Haoyang Biological Manufacture Co.,
China). This study was approved by the Ethics Com-
mittee of Chongqing Medical University and a written
informed consent was obtained from all participants.
Semi-quantitative RT-PCR and quantitative real-time PCR
analysis (qRT-PCR)
Cells were collected for RNA extraction with RNAiso
Plus (Takara, China). RNA concentration and purity was
confirmed by OD260/280 readings, and 1 μg of RNA was
reverse transcribed into cDNA using a PrimeScript® RT
reagent Kit with gDNA Eraser (Takara). Semi-quantitative
PCR amplifications were performed with Taq polymerase
(Takara) on Bio-Rad T100™ Thermal Cycler (Bio-Rad,
USA), and gene expression was compared to β-actin (con-
trol), by agarose gel electrophoresis. Real time PCR
(qPCR) was performed using an SYBR premix Ex Taq™ kit
(Takara) on a Bio-Rad CFX96 Real-time PCR detection
System (Bio-Rad, USA). Then, samples were transferred to
a thermal cycler and DNA was amplified through 40 ther-
mal cycles under the following conditions: denaturation at
95°C for 10 s, annealing at 55°C for 20 s, and extension at
72°C for 20 s. PCR primers used were as follows: 5’-
CCGAGCACTGTGGTTGAGTA-3’ (forward) and reverse
5’-AACTGCATCTGATGGTGGTG-3’ (reverse) for SUZ12,
5’-CAGCCAGCCCAGCACAT-3’ (forward) and 5’-AGCCG
AAGAAACCTCATTGTC-3’ (reverse) for Nrf2, and
forward 5’-CTGAAGTACCCCATCGAGCACGGCA-3’
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G-3’(reverse) for β-actin.
SUZ12 promoter analysis
Genomic DNA of K562 cells was extracted with a Wizard®
Genomic DNA Purification Kit (Promega, USA), and then
the 2,264, 1,375, and 793 bp upstream region fragments of
the SUZ12 gene were amplified by PCR from K562 gen-
omic DNA. 5’-CTCAGAGGATTGGTGTGAGAATTGAA
TGT-3’, 5’-ATGGTTCTATGTTTATAGGTTGGG-3’, and
5’-TGACCACTCTTACGGTGTTTG-3’ were sense primers
of the three nucleotide fragments, respectively. The anti-
sense common primer of the three nucleotide fragments
was 5’-GCCTGGACGTGCTCCATTTTCG-3’.
The three fragments were inserted into promoter-less
vectors pGL3-Basic (Promega), named pGL3-S1, pGL3-
S2, and pGL3-S3, respectively, and the identity of all the
three constructs was confirmed by DNA sequencing.
Next, plasmids and Mig-p210 were co-transfected into
Phoenix-Ampo cells using JetPEI (Polyplus, France),
moreover, to exclude the transfection efficiency factor,
promoter activity analysis was conducted with pRL-TK
(Promega). Cells were harvested 48 h later and assayed
with a dual-luciferase reporter assay system (Promega).
Adenovirus vector construction, production, and
transduction
A SUZ12 promoter, CMV minimal core promoter, and
HSV-TK encoding sequences were obtained by PCR
from pGL3-S1, plasmid pIRES2-EGFP (Clontech, USA)
and pORF9-HSV1tk (Invitrogen, LOCATION), respect-
ively. The ARE domain was chemically synthesized and
cloned into pAdTrack (Invitrogen) by denaturing and




TTTC-3’ (forward) and 5’-AGAATTACACGGCGATCTT
TC-3’ (reverse) for Luc, forward 5’-GCCACCATGGCCTC
GTA-3’ (forward) and 5’-TCAGTTAGCCTCCCCCATCT
C-3’ (reverse) for TK, forward 5’-AGCTTATCCGCAGTC
ACAGTGACTCAGCAGAATCTGATCCGCAGTCACAG
TGACTCAGCAGAATCTGC-3’ (forward) and 5’-TCGAG
CAGATTCTGCTGAGTCACTGTGACTGCGGATCAG
ATTCTGCTGAGTCACTGTGACTGCGGATA-3’ (reverse)
for ARE, forward 5’-TAGGCGTGTACGGTGGGAGGTC
TAT-3’ (forward) and 5’-GGATCTGACGGTTCACTA
AACCAG-3’ (reverse) for CMV.
DNA sequences encoding HSV-TK or luciferase, the
SUZ12 promoter sequence, the CMV minimal core pro-
moter, and the ARE domain were linked into DNA cas-
settes (Figure 1A). Recombinant replication-deficient
adenoviruses were produced using the AdEasy system as
previously described [18]. For Ad transduction, differentmultiplicities of infection (MOI) that yielded similar
transduction efficiency for the four cell lines (~80%)
were used. K562, KCL22, K562/G01 were incubated with
adenoviruses (MOI 500:1) and polybrene (Sigma, USA)
at 10 μg/mL, while HepG2 was incubated with adenovi-
ruses at an MOI of 50:1.
Ad luciferase assay
For the Ad luciferase assay, cells were seeded (1 × 104
cells/well) into 24-well plates, and transduced with Ad-
AS-luc, Ad-S-luc, or Ad-control as described above.
After 72 h, a luciferase assay was performed with a
ONE-Glo™ Luciferase Assay System (Promega) accord-
ing to the manufacturers’ instructions. Results were nor-
malized to protein measured with the Bradford method
and all data were depicted relative to luciferase activity
of Ad-control. Luciferase of Ad-control was driven by
the CMV minimal core promoter, whereas Ad-AS-luc
and Ad-S-luc were driven by ARE/SUZ12 and SUZ12,
respectively.
Cell survival assay
To measure the effects of TK/GCV on BP-CML cell via-
bility, cells were seeded (2 × 103 cells/well) into 96-well
plates, and transduced with Ad-AS-TK, Ad-S-TK, or
Ad-Empty as described above, and then 24 h later, 0–
100 μmol/l GCV was added to the medium. After 48 h
of GCV incubation, medium was replaced with fresh
medium containing GCV. After 0, 24, 48, 72, 96, and
120 h of GCV incubation, cell viability was measured with
a WST assay using a cell counting kit (CCK) (Beyotime,
China), and survival was calculated according to relative
absorbance at 450 nm.
Immunofluorescent assays
Transduced cell cells were fixed in 4% (v/v) paraformal-
dehyde for 20 min, permeabilized for 15 min in PBS
containing 0.1% (v/v) Triton X-100, and then pre-
blocked for 1 h in 1% (w/v) goat serum (Sigma) at room
temperature. Cells were incubated overnight at 4°C
with primary antibodies against SUZ12 (1:350, Cell Signal-
ing, USA), NQO1 (1:200, PTG, USA). Secondary anti-
bodies (1:1,000, anti-rabbit or anti-mouse, Santa Cruz,
CA) were added and incubation proceeded at room
temperature for 1 h in the dark. Nuclei were counter-
stained with DAPI (1:1,000, Sigma).
Western blot
To measure expression of cyclical and apoptotic signal-
ing molecules, cells was seeded (2 × 105 cells/well) into
6-well plates, and transduced with Ad-AS-TK, Ad-S-TK,
or Ad-Empty and 100 μmol/l of GCV as described
above. After 48 h of GCV incubation, cells were lysed in
RIPA lysis buffer. Cell protein was quantified using the
Figure 1 SUZ12 and Nrf2 status in blast crisis CML cells (A) Structures of Ad luciferase reporter (Ad-AS-luc and Ad-S-luc) and Ad TK vectors
(Ad-AS-TK and Ad-S-TK). The ARE construct contains 2 AREs from human NQO1 modifier subunit, and the SUZ12 promoter contains a 2.3 kb
upstream fragment. (B) Relative SUZ12 and Nrf2 mRNA of mononuclear cells from five normal bone marrow and six blast phase samples, by
RealTime RT-PCR. NBM: normal bone marrow; BP: blast phase. (C) Relative SUZ12 and Nrf2 mRNA in K562, KCL22, K562/G01, and HepG2 cells
by RealTime RT-PCR analysis. Data are depicted as relative to actin mRNA, respectively. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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transferred to PVDF membranes, and then immuno-
blotted with primary antibody against Bcl-2, Bax, and
cyclin D1 (Cell Signaling), followed by HRP-conjugated
secondary antibody. Protein band intensity was quantified
via ECL (Millipore, USA) with a Viagene Cool Imager™
(Viagene, USA).
Apoptotic analysis
To measure apoptosis, cells were seeded (2 × 105 cells/
well) into 6-well plates, and transduced with Ad-AS-TK,
Ad-S-TK, or Ad-Empty as described above, and further
incubated with 100 μmol/l of GCV. After observing
apoptosis with Wright’s staining, apoptosis was mea-
sured with PE Annexin V (BD Biosciences, USA), ac-
cording to the manufacturer’s instructions, followed by
cell counting with a Gallios flow cytometer (Beckman
Coulter, USA).
Statistical analysis
All experiments were conducted at least three times,
and data are expressed as means ± SD. Statistical differ-
ences between groups were measured with a Student’s t-
test, and statistical differences across cell types and Ad
types were measured with a 2-way ANOVA post hoc test
(P <0.05 were considered statistically significant).Results
Status of SUZ12 and Nrf2 in BP-CML
mRNA of both SUZ12 and Nrf2 was measured in three
BP-CML-derived cell types (K562, KCL22, and K562/
G01), and a HepG2 hepatoma cell line. Figure 1C shows
statistically significant differences of SUZ12 and Nrf2
mRNA between BP-CML cell lines and HepG2 (P
<0.05), SUZ12 and Nrf2 mRNA were both significantly
higher in the CML blast crisis-derived cell lines com-
pared to HepG2 cells. To measure SUZ12 and Nrf2
mRNA in bone marrow mononuclear cells from five
healthy donors and six blast phase patients, we used
qRT-PCR and observed significant increases in SUZ12
and Nrf2 in blast crisis samples compared to normal
donor samples (P <0.05). These data agreed with previ-
ous published reports [14,19].
SUZ12 and ARE/SUZ12 promoter activity in different cell
lines
Using bioinformatics and the literature [12], the 2,264 bp
(−1,793 to +471), 1,375 bp (−904 to +471), and 793 bp
(−322 to +471) upstream fragments of the SUZ12 gene
were inserted to pGL3-basic reporter plasmids, and lucif-
erase activity of the constructed reporter plasmids was
measured in Phoenix-Ampo/Mig-p210 cell to confirm the
active promoter sequence. Promoter activity of the 2.3 kb
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1.4 kb fragment; thus the distal region of the SUZ12 pro-
moter had more basal promoter activity under control
conditions (Figure 2A).
Next, we measured basal SUZ12 or ARE/SUZ12 pro-
moter activity in K562, KCL22, K562/G01, and HepG2
cells by transducing cells with the Ad-control, Ad-S-luc
or Ad-AS-luc (construct of Ad-control, Ad-S-luc, or Ad-
AS-luc, see §Materials and Methods). Luciferase assay
data indicated that K562/G01 had the most ARE/SUZ12
activity, and this was 102-fold greater than the Ad-control,
whereas HepG2 had the least activity (Figure 2B). Also,
data confirmed significantly higher and specificer pro-
moter activity of the ARE/SUZ12 composite component
in CML blast crisis-derived cells (p < 0.05).
Viability of BP-CML cells transduced with Ad-AS-TK or
Ad-S-TK
To measure viability of cells transduced with Ad-AS-
TK/GCV, Ad-S-TK/GCV, or Ad-Empty/GCV, a WST
assay was used. As shown in Figure 3, we observed that
K562, KCL22, and K562/G01 cells treated with Ad-AS-Figure 2 Basal and inducible SUZ12 activity in Bcr/abl+ cells.
(A) Promoter activity assay of different SUZ12 upstream fragments via
dual-luciferase reporter assay in Bcr/abl+PHA cells. Bcr/abl+PHA cells
were transfected as depicted in Methods and luciferase activity was
measured 48 h later. Data are presented as a fold-changes ± SD of
firefly/Renilla (F/R) ratios, means ± SEM, n=3. (B) Promoter activity assay
of SUZ12 or ARE/SUZ12 by ONE-Glo™ luciferase assay in K562, K562/
G01, KCL22, and HepG2. Cells were transduced as depicted in Methods
and luciferase activity was measured 72 h later. Data are normalized to
protein and are presented as fold-increases versus Ad-control, means ±
SEM, n=3. *, P < 0.05; **, P < 0.01; ***, P < 0.001.TK/GCV were less viable compared to cells treated with
Ad-S-TK/GCV (P <0.05). For example, absorbance of
K562/G01 incubated with 10, 50, and 100 μmol/l of
GCV was 0.44 (SD=0.02), 0.33 (SD=0.02) and 0.23
(SD=0.01) for Ad-AS-TK, and 0.59 (SD=0.03), 0.41
(SD=0.02) and 0.34 (SD=0.04) for Ad-S-TK, respectively,
where reduction of cell viability by Ad-AS-TK/GCV
were significantly more sharp (P <0.05). Loss of cell via-
bility with Ad-AS-TK/GCV treatment suggested that
Ad-AS-TK effectively killed BP-CML cells.
After incubating cells with Ad-AS-TK or Ad-S-TK and
increasing concentrations of GCV (0–100 μmol/l), K562,
KCL22, and K562/G01 cell viability progressively de-
creased. Both Ad-AS-TK/GCV and Ad-S-TK/GCV
treatment showed significant GCV-dependent manner
reduction in cell viability (Figure 3B). After cells were
incubated in 100 μmol/l GCV and Ad-AS-TK for 5 days,
K562, KCL22, and K562/G01 cells were almost eradi-
cated. In contrast to BP-CML cells, HepG2 cell viability
was only slightly affected after incubation with Ad-AS-
TK or Ad-S-TK and 100 μmol/l GCV, and more than
60% of transduced HepG2 cells were viable (Figure 3A).
An immunofluorescent assay with anti-SUZ12 antibody
revealed that fewer than 50% Ad-AS-TK transduced
BP-CML cells were SUZ12-positive, and more than
70% control cells were SUZ12-positive (Figure 4). The
2.3 kb exogenous SUZ12 fragment of Ad-AS-TK com-
petes with the endogenous SUZ12 gene for the same
transcription factor binding, reducing endogenous
SUZ12 promoter activity and SUZ12 expression.
Apoptosis of BP-CML cells transduced with the ARE/
SUZ12 dual-specific TK/GCV system
To investigate whether Ad-AS-TK/GCV could exhibit
enhanced apoptotic effects in BP-CML cells, the Ad
transduced cells, treated with 100 μmol/l GCV for an
additional 48 h, were assayed with Annexin V PE. The
results showed that Ad-AS-TK was better at inducing
cell apoptosis in ROS-signal activated BP-CML cells
than Ad-S-TK (Figure 5A and B). After a 48 h incuba-
tion, apoptotic cells increased in Ad-AS-TK transfected
cells compared to Ad-S-TK or empty adenovirus. k562
cells treated with Ad-AS-TK had the greatest degree of
cell death (~51%), compared to k562 treated with Ad-S-
TK (~28%). HepG2 cells treated with TK adenoviruses
had the least amount of cell death (~12% for Ad-AS-
TK, ~7% for Ad-S-TK). Thus, the Ad-AS-TK/GCV sys-
tem can effectively and selectively induce apoptosis of
BP-CML cells.
Expression changes in cell cycle-related and apoptosis-
related molecules
To test whether the Ad-AS-TK/GCV system altered ex-
pression of cycle-related and apoptosis-related proteins,
Figure 3 Cell survival assay of BP-CML cells with an ARE/SUZ12-regulated TK/GCV system. BP-CML cell lines and control cells were transduced
with Ad-S-TK, Ad-AS-TK, or empty adenovirus, and cultured in different concentrations of GCV. Cell viability was assessed via CCK8 assay (A) with
100 μmol/l GCV treatment at d0, d1, d2, d3, d4, and d5 and (B) with 0–100 μmol/l GCV treatment at d5. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 4 Immunofluorescent staining to measure SUZ12 in BP-CML cells with an ARE/SUZ12-regulated TK/GCV system. CML blast crisis cells were
transduced with PBS, Ad-AS-TK, or empty adenovirus, and cultured in 100 μmol/l GCV for 48 h.
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Figure 5 Apoptotic effects of BP-CML cells with an ARE/SUZ12-regulated TK/GCV system. BP-CML cell lines and control cells were transduced
with Ad-S-TK, Ad-AS-TK, or empty adenovirus, and further cultured in 100 μmol/l GCV. The percentage of apoptotic cells was determined by
annexin V–PE/7-AAD staining followed by 2-color flow cytometric analysis (A). Data represent average percentage ± SEM, n=3. *, P < 0.05; **, P < 0.01;
***, P < 0.001 (B).
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Figure 6 shows that BP-CML cells treated with the Ad-
AS-TK/GCV system, compared with Ad-S-TK/GCV or
empty adenovirus, had more Bax expression, and de-
creased Bcl-2 and Cycline D1 expression. Thus, the dually
regulated Ad-AS-TK/GCV system could induce apoptosis
or affect the cell cycle of BP-CML cells, compared with
the Ad-S-TK/GCV system. These data agreed with Wright
staining analysis (Additional file 1: Figure S1).Discussion
To date, gene therapy has shown promise for thera-
peutic applications but reported adverse events have
caused concern in the scientific community about the
safety of these approaches [20–22]. To improve safety,
tightly regulated TK gene expression for blast-phase
leukemia cells was conducted with a dual-specific
composite promoter components in our study. Our
data confirm the feasibility and efficacy of an ARE/
Figure 6 Expression of cycle-related and apoptotic molecules in BP-CML cells with an ARE/SUZ12-regulated TK/GCV system. Bcl-2, Cycline D1,
and Bax. CML blast crisis cells were transduced with Ad-S-TK, Ad-AS-TK, or empty adenovirus, and cultured in 100 μmol/l GCV for 48 h. Expression
of Bcl-2, Cyclin D1, and Bax analyzed with Western blot (actin internal control).
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High constitutive expression of SUZ12 has been re-
ported to drive proliferation, impair differentiation, and
disrupt histone modification, which induces deregulation
of transcriptional networks and aggressive leukemia. Piz-
zatti’s group reported that SUZ12 was overexpressed in
BP-CML, and that this was due to SUZ12 promoter ac-
tivation by constitutively activated WNT pathway mol-
ecules including catenin P120, WNT11, and WNT5A.
Our data confirm a sharp increase in SUZ12 mRNA in BP-
CML patient samples. Ridinge and colleagues reporeted
that SUZ12 bound to the Bim promoter represses Bim
pro-apoptotic factor transcription, thus inhibiting mito-
chondrial apoptosis of leukemia cells [23]. Meanwhile, Shi
and coworkers reported that shRNA-mediated suppres-
sion of SUZ12 lead to proliferation arrest and initiation
of differentiation of leukemia cells, and had minimal ef-
fects on the growth of several non-leukemia-transformed
hematopoietic cell lines [24]. Similarly, Villa’ group re-
vealed that knockdown of SUZ12 can revert not only
histone modification but also DNA demethylation of
PML-RARα target genes, contributing granulocytic dif-
ferentiation in leukemic cells [25]. Therefore, the 2.3 kb
upstream fragment harboring substantial promoter activity
was measured with a luciferase assay and this fragment
was cloned to regulate specific expression of the down-
stream TK gene in our study. To more tightly and strongly
regulate TK expression, a combination of the ARE enhan-
cer and the SUZ12 promoter was constructed.
Oxidative stress, an imbalance between the production
and disposal of ROS, has been shown to be associated
with CML progression and TKI resistance via oxidative
DNA damage [26–30]. In response to oxidative stress, ac-
tivated Nrf2 recognizes and binds to ARE of cytoprotec-
tive and detoxification genes, including NAD(P)H:quinoneoxidoreductase (NQO1), and then Nrf2 stimulates tran-
scriptional activation of genes in CML cells. We cloned
the ARE of the NQO1 gene and inserted this into up-
stream regulatory elements to regulate TK expression. Ad-
AS-Luc had more luciferase activity in BP-CML cells, and
Ad-AS-TK synergized ARE and the SUZ12 promoter for
cell killing.
Due to basal promoter activity, apoptosis of BP-CML
cells transduced with Ad-S-TK/GCV occurred, and the
ARE/SUZ12 dual-specific Ad-AS-TK/GCV system con-
ferred greater apoptosis of CML blast crisis cells. Likely
tight and augmented TK regulation by ARE/SUZ12
composite components may help eradicate leukemia
cells. ARE performed a specific enhancer role that ARE
enhanced the translation of the downstream TK gene in
CML cell. Also, the 2.3 kb exogenous SUZ12 fragment
of Ad competes with the endogenous SUZ12 gene for
the same transcription factor binding, causing SUZ12
expression loss (Figure 4) and cell proliferation arrest
[24]. Third, Nrf2 functions to activate translation of
cytoprotective genes and protect cells from electrophilic
and oxidative damage in normal cells. However, in can-
cerous cells, Nrf2 is pro-tumor as the same cytoprotec-
tive genes protect human leukemia cells from apoptotic
signals and enhance cancer cell chemo-resistance [31].
The exogenous ARE of the Ad competes with the en-
dogenous ARE of cytoprotective genes for Nrf2, thus at
least partly blocking endogenous Nrf2 signaling path-
ways of leukemia cells. However, our immunofluorescent
assay with anti-NQO1 antibody did not confirm signifi-
cant differences in NQO1 expression in cells incubated
with Ad-AS-TK or Ad-Empty (data not shown). There-
fore, therapeutic efficacy was enhanced via synergism of
ARE/SUZ12 specific regulation. This suggests that Ad-
AS-TK may be beneficial, safe, and efficacious for blast
crisis CML.
Zu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:56 Page 9 of 10Blast crisis as first presentation of CML accounts for
10% of all CML cases [32], with a median survival of less
than 6 months, while the rest 90% cases diagnosed with
CP-CML have been potentially in process to blast crisis.
Median survival of CP-CML is estimated at a median of
25 to 30 years, and the blastic transformation rate has
estimated at 1% to 1.5% per year in the imatinib era,
which means 25% to 45% CP-CML would be into blast
phase [33,34]. Nowadays, CML patients have multiple
treatment options, including five TKIs (imatinib, niloti-
nib, dasatinib, bosutinib, and ponatinib), omace-taxine
(protein synthesis inhibition), and several older agents
(hydroxurea, interferon alpha, busulfan, 6-mercaptopurine,
cytarabine, decitabine, etc.). TKIs monotherapy or in com-
bination with chemotherapy may serve as a preferred op-
tion for BP-CML, and provide a median survival of 9–12
months in BP CML. As a novel way of treatment, gene
therapy bring a new hope for BP CML patients. As a po-
tential treatment strategy of BP-CML, there is still a ques-
tion whether Ad-AS-TK/GCV system is efficacious for
primary leukemic cells of all the BP-CML patients. In our
study, an adenoviral type 5 (Ad5) vector was introduced
into the systemic delivery of modified AS-TK construct,
and the effect of Ad-AS-TK/GCV system is directly as-
sociated with adenoviral gene transfer efficiency into
hematopoietic cells. Efficient gene transfer with Ad5
vectors generally depends on the initial attachment of
their fiber, which binds the coxsackie–adenovirus re-
ceptor (CAR) of cells, and their subsequent internaliza-
tion. Primary leukemic cells of some CML patients lack
CAR and are therefore resistant to Ad5 transduction,
gene transfer efficiency of Ad5 can differ greatly among
individual CML patient cells [35] (gene transfer rates of
RGD-Ad5 can be 30 ~ 80%), which means different
apoptosis effect of Ad-AS-TK/GCV system for different
CML patient cells. Currently, integrating vectors derived
from retroviruses and lentiviruses remain a preferred
choice for their preferable efficiency in haematological
clinical trials, however, integration of exogenous gene
quasi-randomly throughout the human genome has been
reported to cause an alarming incidence of vector-induced
malignancy [36]. The stable, safe and effective gene trans-
fer strategies should be further exploited to deliver ex-
ogenous gene into hematopoietic cells to overcome
technology bottleneck of clinical leukemia gene therapy.
Conclusions
In the study, we constructed an ARE/SUZ12 dual-specific
TK/GCV system for blast phase leukemia gene therapy.
The system was composed of two regulatory elements, an
ARE for oxide stress regulation and a SUZ12 promoter for
specific promoter activity in BP-CML cells. Our work
suggests the feasibility of an ARE/SUZ12-regulated TK/
GCV system for selectively eliminating BP-CML cells,suggesting that suicide gene engineering may be an ef-
fective strategy for treating BP-CML.
Additional file
Additional file 1: Figure S1. Apoptosis analysis with Wright’s staining
in BP-CML cells with an ARE/SUZ12-regulated TK/GCV system. CML blast
crisis cells were transduced with Ad-S-TK, Ad-AS-TK, or empty adenovirus,
and cultured in 100 μmol/l GCV for 48 h. Wright staining analysis of K562
(A), K562/G01 (B), KCL22 (C) for different groups.
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